Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

15.53
+0.18001.17%
Post-market: 15.530.00000.00%19:30 EDT
Volume:104.91K
Turnover:1.63M
Market Cap:380.55M
PE:-1.31
High:16.16
Open:15.54
Low:15.20
Close:15.35
52wk High:45.00
52wk Low:10.50
Shares:24.50M
Float Shares:10.79M
Volume Ratio:0.57
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.8281
EPS(LYR):-16.0562
ROE:-93.28%
ROA:-34.18%
PB:1.63
PE(LYR):-0.97

Loading ...

Citizens biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 03

Lyell Immunopharma to Join H.C. Wainwright Cell Therapy Virtual Conference Fireside Chat

Reuters
·
Jun 25

Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner

Reuters
·
Jun 19

Lyell Immunopharma Shareholders Back Governance at 2026 Meeting

TIPRANKS
·
Jun 16

Lyell Immunopharma shareholders approved auditor Ernst & Young for 2026 fiscal year

Reuters
·
Jun 16

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 15

BRIEF-Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma

Reuters
·
Jun 13

Lyell Immunopharma - Pinacle Pivotal Trial Data Update Expected H2 2026; Bla Submission Planned H2 2027

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - Ronde-Cel Treated Over 100 Patients in 2L and 3L+ Lbcl With 97% Manufacturing Success Rate

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients With Large B-Cell Lymphoma at European Hematology Association 2026 Congress

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - No Grade 3 or Higher Crs and Low Rates of Grade 3 or Higher Icans Reported

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma says ronde-cel Phase 1/2 study in LBCL shows no grade 3+ CRS

Reuters
·
Jun 13

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of Lyl273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - No Difference in GCC Car T-Cell Expansion With or Without Gi Prophylaxis

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Maximum Tolerated Dose Not yet Determined

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Additional Phase 1 Data and FDA Meeting Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Lyell Immunopharma presents Phase 1/2 safety, translational data for ronde-cel in relapsed/refractory large B-cell lymphoma at EHA 2026

Reuters
·
Jun 05